Compare NVCR & NNNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NVCR | NNNN |
|---|---|---|
| Founded | 2000 | 2021 |
| Country | Switzerland | Germany |
| Employees | N/A | 27 |
| Industry | Medical/Dental Instruments | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.5B |
| IPO Year | 2015 | 2025 |
| Metric | NVCR | NNNN |
|---|---|---|
| Price | $13.57 | $34.00 |
| Analyst Decision | Buy | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $28.42 | N/A |
| AVG Volume (30 Days) | ★ 1.8M | 37.8K |
| Earning Date | 10-30-2025 | 04-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.06 |
| Revenue | ★ $642,269,000.00 | $8,185,146.00 |
| Revenue This Year | $9.75 | N/A |
| Revenue Next Year | $5.62 | N/A |
| P/E Ratio | ★ N/A | $619.66 |
| Revenue Growth | 11.17 | ★ 21.95 |
| 52 Week Low | $10.70 | $5.18 |
| 52 Week High | $32.06 | $55.65 |
| Indicator | NVCR | NNNN |
|---|---|---|
| Relative Strength Index (RSI) | 59.44 | 54.45 |
| Support Level | $12.30 | $31.18 |
| Resistance Level | $13.97 | $35.55 |
| Average True Range (ATR) | 0.55 | 5.14 |
| MACD | 0.09 | 0.14 |
| Stochastic Oscillator | 77.21 | 37.79 |
NovoCure Ltd is an oncology company with a propreitary platform technology in United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis and other products and technologies for the treatment of Glioblastoma, Non-smell cell lung cancer and Pancreatic cancer. Geographically, the company derives majority of its revenue from the United States and rest from Germany, Japan and other markets.
Anbio Biotechnology is a medical device company focused on in vitro diagnostics. It offers laboratory, wellness, at-home, and point-of-care (POCT) in vitro diagnostic (IVD) solutions to detect a wide range of biomarkers associated with critical medical domains encompassing infectious diseases, cancer, cardiovascular diseases, inflammation, drug abuse, endocrine disorders, renal disease, pharmacogenomics, and diabetes. Its product portfolio comprises AF-1200 Fluorescence Immunoassay Analyzer, SHA-100 Dry Chemistry Analyzer, Ferritin Rapid Test Kit, Dengue NS1 Rapid Test, Multi-HBV Rapid Test, COVID-19 Test Kit (Real-time PCR), and others. Geographically, the company generates maximum revenue from the European Union, followed by South America, Asia Pacific, North America, and other regions.